Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study



Hyperpolarized (HP) 13C-pyruvate MRI is a stable-isotope molecular imaging modality that provides real-time assessment of the rate of metabolism through glycolytic pathways in human prostate cancer. Heretofore this imaging modality has been successfully utilized in prostate cancer only in localized disease. This pilot clinical study investigated the feasibility and imaging performance of HP 13C-pyruvate MR metabolic imaging in prostate cancer patients with metastases to the bone and/or viscera.


Six patients who had metastatic castration-resistant prostate cancer were recruited. Carbon-13 MR examination were conducted on a clinical 3T MRI following injection of 250 mM hyperpolarized 13C-pyruvate, where pyruvate-to-lactate conversion rate (kPL) was calculated. Paired metastatic tumor biopsy was performed with histopathological and RNA-seq analyses.


We observed a high rate of glycolytic metabolism in prostate cancer metastases, with a mean kPL value of 0.020 ± 0.006 (s−1) and 0.026 ± 0.000 (s−1) in bone (N = 4) and liver (N = 2) metastases, respectively. Overall, high kPL showed concordance with biopsy-confirmed high-grade prostate cancer including neuroendocrine differentiation in one case. Interval decrease of kPL from 0.026 at baseline to 0.015 (s−1) was observed in a liver metastasis 2 months after the initiation of taxane plus platinum chemotherapy. RNA-seq found higher levels of the lactate dehydrogenase isoform A (Ldha,15.7 ± 0.7) expression relative to the dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8 ± 0.9).


HP 13C-pyruvate MRI can detect real-time glycolytic metabolism within prostate cancer metastases, and can measure changes in quantitative kPL values following treatment response at early time points. This first feasibility study supports future clinical studies of HP 13C-pyruvate MRI in the setting of advanced prostate cancer.


Metastatic castration-resistant prostate cancer (mCRPC) is the most lethal form of the disease, accounting for 31,000 deaths/year in the United States [1]. More than 90% of patients with mCRPC develop osseous metastases and nearly half have bone as the only site of the disease [2, 3]. Visceral metastases occur in 10–15% of mCRPC patients and are associated with high disease burden and poor prognosis [4, 5]. Despite the emergence of multiple therapies that have been shown to prolong overall survival, including androgen pathway inhibitors, immunotherapy, radiopharmaceuticals, and chemotherapeutics, there is an unmet need for novel therapies to further improve treatment outcomes [3, 6, 7].

A limitation to the development of novel systemic therapies in mCRPC, especially with bone predominance without measurable disease by conventional imaging criteria, is the lack of validated imaging biomarkers to provide real-time response monitoring. Automated bone indices of radionuclide bone scans have not been sufficiently prospectively validated, and provide minimal information with respect to direct tumor metabolic activity. Also, changes in bone scintigraphy with response to therapy can be slow to occur and are complicated by flare phenomena and differences in uptake between sclerotic versus lytic lesions [8]. Newer PET analogs, including agents targeting prostate-specific membrane antigen, have shown promise as a diagnostic tool, but have limited and conflicting data to support their use to monitor therapeutic response and resistance [9, 10].

Hyperpolarized 13C MRI (HP 13C MRI) is a stable-isotope molecular imaging approach that probes pyruvate-to-lactate metabolism mediated by the upregulation of LDH enzymatic activity in cancer due to the Warburg effect [11,12,13,14] (Fig. 1). High glycolytic activity and rapid pyruvate-to-lactate conversion are signatures of aggressive cancer [13, 15, 16]. There is also a broad consensus that the pharmacologic action of chemotherapy is tightly coupled with metabolic pathways, and responses to chemotherapy might be reflected as modulations of cancer metabolism [17,18,19]. Heretofore HP 13C-pyruvate MRI has been successfully utilized in prostate cancer only in localized disease. This imaging modality has been used to detect metabolic responses to chemohormonal therapy in primary prostate cancer [20], at earlier time points than conventional multiparametric MRI.

Fig. 1
figure 1

An illustration of LDH-mediated aerobic glycolysis and relevant metabolic pathways

In the current pilot imaging study, we aimed to broaden the scope of HP 13C-pyruvate MRI to the metastatic CRPC setting, with direct visualization of skeletal and visceral metastases, in order to provide real-time assessment of tumor metabolism and metabolic response to therapy.


Patient selection

Key eligibility criteria included histologic evidence of prostate cancer, progressive mCRPC by PCWG2 criteria [7], ECOG performance status of 0 or 1, and adequate end organ function. All patients underwent restaging CT and bone scans prior to enrollment, and had at least one identified lesion amenable to HP 13C MRI. Patient recruitment and HP 13C-pyruvate studies were conducted in compliance with an IRB-approved protocol (NCT02911467), and all patients provided written informed consent.

HP 13C patient MRI studies

GMP [1−13C]pyruvic acid (Sigma-Aldrich Isotec, Miamisburg OH) was prepared and loaded in pharmacy kits in accordance with the IRB- and FDA IND-approved stable-isotope manufacturing process. The pyruvic acid was polarized in a 5T SPINLab (GE Healthcare, Chicago IL) clinical trial polarizer for 2.5–3 h. Dissolutions yielded 237 ± 10 mM sterile pyruvate with 37.1 ± 3.2% polarization, 0.6 ± 0.4 μM residual radical and 31.0 ± 0.6 °C temperature, 7.5 ± 0.3 pH, 63 ± 4 s dissolution-to-injection time. A pharmacist oversaw the automatic quality control and integrity of the sterilization filter, and released the dose for injection once sterility and safety criteria were met [21, 22].

All studies were conducted on a clinical 3T MRI (MR750, GE Healthcare) equipped with multinuclear spectroscopy capabilities. A custom surface coil with figure-eight configuration was applied for both 13C transmit and receive. A 16-channel abdominal array (GE Healthcare) was used for proton imaging.

Follow-up 13C-pyruvate MRI was optional after the initiation of systemic therapy for the treatment of mCRPC.

Data acquisition and analysis

The HP-13C acquisition was conducted using a 2D dynamic MR spectroscopic imaging pulse sequence with a slice-selective spectral-spatial excitation, followed by phase-encode and echo-planar spectroscopic imaging readout [11]. Pulse sequence parameters were as follows: 130 ms/3.5 ms TR/TE, 2–3 cm slice thickness, 1.2–1.5 cm in plane spatial and 3 s temporal resolutions, 60 s acquisition window, 545 Hz bandwidth, constant flip angle through time with pyruvate 10°, and lactate 20°. Scan started 5 s following the end of the injection. Patients were asked to hold their breath as long as possible, after which they were instructed to breathe gently and resume breath holding as tolerated. Conventional proton T1-weighted spoiled gradient-echo (TR/TE = 4.3 ms/1.9 ms) images were acquired for anatomic reference. Dynamic HP 13C MRI datasets were processed by applying even–odd lobe phasing, B0-shift correction, tensor-low-rank signal enhancement [23], spectral baseline correction [24], followed by a phase-sensitive peak quantification. The pyruvate-to-lactate conversion rate, kPL, was evaluated using an inputless single-compartment two-site exchange model [25], and the value reported was the maximum over ROI of the lesion identified on proton MRI. Total carbon signal-to-noise ratio (SNR) was reported as summed SNR of 13C-labeled tracers averaged over time. The image processing tools are located under—SIVIC Image Processing/Display:, Hyperpolarized MRI Toolbox:

Metastatic tumor biopsy acquisition and analysis

CT-guided metastatic tumor biopsies following HP MRI acquisition were obtained in five out of the six patients enrolled in the study (Table 1). Tumor biopsies were obtained for both fresh frozen processing and formalin fixed paraffin embedded (FFPE) processing. FFPE tissues were used for histologic diagnosis, while frozen tissue underwent Laser Capture Microdissection for RNA-seq profiling as previously described [6]. Expression levels reported as log(1 + (TPM × 106)). Processed RNA-seq data are located in the Supplementary Materials.

Table 1 A summary of clinically relevant information from each patient


Patient characteristics

Six patients were enrolled in this pilot feasibility study. The baseline characteristics of the patients are shown in Table 1. All patients had progressive mCRPC at study entry. Five of the patients underwent CT-guided metastatic tumor biopsy of the target lesions following completion of baseline 13C-pyruvate MRI. No adverse events were reported throughout this study.

HP 13C-pyruvate MRI detects high k PL in bone and liver metastases

The rate of conversion of pyruvate to lactate (kPL) from target lesions in each patient is listed in Table 2. There was high kPL in both bone and liver metastases, with mean kPL of (0.020 ± 0.006 s−1) and (0.026 ± 0.000 s−1), respectively [26]. Regions of high kPL were consistent with CT and MRI radiographic findings of metastatic disease presence, as shown in the representative kPL image overlays for the target lesions (Fig. 2a, Supplementary Figs. 1–4).

Table 2 Findings from HP 13C MRI including kPL, and RNA expression of key genes
Fig. 2
figure 2

a Patient 1 (75 years old) was diagnosed with metastatic castration-resistant prostate cancer with several large osteoblastic lesions throughout the left hemipelvis and involving left femur. CT identified a relatively osteolytic lesion in left ilium (Green arrows), measuring 9.9 × 4.1 cm. The lesion was infiltrative, causing destruction of the bone cortex and extension into the surrounding soft tissues. T1-weighted (T1w) spoiled gradient-echo MRI was used to target the same lesion observed on CT for the HP 13C MR acquisition. Regions of high pyruvate-to-lactate conversion rate (kPL) correlated with the osseous lesion on CT and hypointensity on T1w MRI. kPL was estimated 0.013 (s−1). b The paired bone biopsy demonstrated discrete regions of adenocarcinoma and treatment-emergent small cell neuroendocrine differentiation

The liver mass of patient six showed considerable intratumoral heterogeneity (Supplementary Fig. 4b). Maximum kPL = 0.025 (s−1) was found in viable tumor, whereas kPL = 0.004 (s−1) was observed in a necrotic-appearing region identified both on CT and the delayed phase of contrast T1-weighted images.

Table 2 also summarizes the total carbon SNR for each study. The total carbon SNR was 117 ± 126 in bone metastases (N = 4), and 85 ± 7 between liver involvements (N = 2). In general, the SNR in all cases was adequate for reliable kPL fitting (standard error metric σkPL = 0.005 ± 0.003) [27].

In all five patients with paired 13C-pyruvate MRI and CT-guided biopsy of the target lesions, the histological evidence of metastatic prostate cancer was detected. In four of the five cases, the histology demonstrated poorly differentiated adenocarcinoma. In one patient (Patient 1), the paired metastatic tumor biopsy demonstrated discrete regions of adenocarcinoma and treatment-emergent small cell neuroendocrine differentiation (Fig. 2b) [6].

Higher levels of gene expression of the lactate dehydrogenase isoform A (Ldha,15.7 ± 0.7) relative to the dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8 ± 0.9) were detected on RNA-seq of the target metastatic biopsies (Table 2), consistent with enhanced aerobic glycolysis detected in the rate of conversion of pyruvate to lactate on HP 13C MRI. No significant difference in Ldha or Pdha1 expression was observed in the patients imaged in this study compared with a previously published cohort of metastases from 200 men with mCRPC (Ldha: 15.1 ± 1.1, p > 0.17; Pdha1: 12.0 ± 0.9, p > 0.06, Wilcoxon ranked sum test) [6].

HP 13C MRI detected a metabolic rate decrease in a metastasis following chemotherapy

Patient 2 had mCRPC with liver metastases and low serum PSA level. Carboplatin + docetaxel chemotherapy was started 24 days after the baseline HP 13C MRI study (Fig. 3c). Follow-up HP MRI study 62 days after the initiation of treatment demonstrated a 42% decrease in pyruvate-to-lactate conversion rate kPL, from 0.026 to 0.015 s−1, in the target liver lesion (Fig. 3a). This was accompanied by interval decrease of the lesion size (Fig. 3b, 19.3–11.8 mm, 39%) based on RECIST 1.1 criteria, along with serum PSA decline of >50% from baseline (38–13.4 ng/ml), consistent with systemic treatment response.

Fig. 3
figure 3

Patient 2 (57 years old) was diagnosed with CRPC that metastasized to liver. The patient was previously treated with enzalutamide and an investigational agent (BET inhibitor, phase I) with clinical progression. Chemotherapy of carboplatin and docetaxel started ~1 month post baseline HP 13C scan, and follow-up was 2 months after initiation of therapy. a A decrease in pyruvate-to-lactate conversion rate kPL was observed from 0.026 to 0.015 (s−1) after 2 months of chemotherapy. Note the increase in pyruvate and lactate at 50–60 s post injection. Most likely this is predominately due to vascular contributions coming from intestines. b Follow-up 2 months after initiation of therapy found a decrease in lesion size (19.3–11.8 mm) indicating therapeutic response based on RECIST criteria. c In addition, serum PSA decreased from 38–13.4 ng/ml also indicating therapeutic response. HA arterial phase, PV portal venous phase


This work reports the results of the first-ever pilot imaging study of prostate cancer metastases using HP 13C-pyruvate MRI. This study demonstrates the feasibility of detecting real-time metabolic activity of metastases and capture therapeutic response with this emerging stable-isotope molecular imaging method. Correlation with paired metastatic biopsy demonstrated high-grade prostate adenocarcinoma, including in one case, evidence of neuroendocrine differentiation.

The high pyruvate-to-lactate conversion rate, kPL, via upregulated LDH activity in cancer, known as Warburg effect, reflects cancer aggressiveness, and decrease in kPL can reflect therapeutic response [14, 20]. Overall, the pyruvate-to-lactate conversion rate kPL found in bone (0.020 ± 0.006 s−1) and liver (0.026 ± 0.000 s−1) lesions was either higher than or comparable with that of high-grade primary prostate cancer (0.013 ± 0.003 s−1) in a cohort imaged prior to radical prostatectomy with whole mount section pathologic correlation [26]. These high kPL values were correlated with the metastatic biopsy findings of high-grade adenocarcinoma or mixed high-grade adenocarcinoma and small cell neuroendocrine phenotypes in the patients studied in this report.

Elevated Ldha expression in prostate cancer is known to be associated with aggressive phenotypes and resistant to therapy [28,29,30]. The high Ldha expression relative to Pdha1 in this study was consistent with a larger published mCRPC cohort [6], reflective of enhanced aerobic glycolysis, whereas in normal prostate epithelial cells the glucose metabolism favors oxidative phosphorylation, and Pdha1 expression should predominate (Fig. 1). This suggested that the metabolic features observed in this study using HP 13C-pyruvate MRI could potentially serve as a representative cross-section of a much larger patient population with different metastatic sites and types of cell morphology.

A previous study in primary prostate cancer indicated that kPL reflected early response and resistance to androgen pathway inhibition [20]. In this communication we observed a correlation between decreased kPL and clinical response to the combination of platinum plus taxane chemotherapy in a patient with mCRPC. Although preliminary, these findings suggest that imaging metabolic signatures using HP 13C-pyruvate MR could potentially report responses to a broader range of oncogenic pathway inhibition and drug targets, and may be less susceptible to the upregulation of membrane protein expression secondary to ADT [31, 32]. These data suggest that the prospective evaluation of HP 13C-pyruvate as a response biomarker in mCRPC patients treated with AR-targeting and cytotoxic chemotherapy is warranted.

Spatially, regions of high kPL showed good alignment with radiographic findings of metastases using bone scan, CT, and proton MRI. Temporally, the time-to-peak of pyruvate bolus was 29 ± 3 s in pelvic bone cases, 23 s in the rib case, 34 ± 4 s among the liver cases. The bolus delivery timing was generally consistent with contrast CT/MRI [33], and are deemed reasonable in light of hemodynamic variations between subjects, and also the vitals of individual subject at the time of the scan. The inputless kPL model applied in this study is relatively immune to variations in bolus characteristics [25].

Differential kPL was observed between viable and necrotic-appearing regions of Patient 6’s liver lesion (Supplementary Fig. 4b). These findings are consistent with other emerging reports of intra- and inter-tumoral heterogeneity in mCRPC [34] and highlight the potential utility of this imaging tool to clarify tumor biology with real-time metabolic monitoring [34,35,36,37]. The kPL heterogeneity between metastatic sites/individual patients and its biological underpinning calls for future investigation.

This study also demonstrated that this technology can provide quantitative metrics of the delivery/uptake of the injected hyperpolarized carbon isotope by measuring the total carbon SNR summing the 13C signal observed from the hyperpolarized pyruvate bolus and downstream metabolic products. Conceptually similar to SUV in PET, total carbon SNR is a metric of delivery and uptake. Of the pelvic bone involvements, patient 1, whose lesion appeared relatively more lytic on CT (Fig. 2a), had higher mean total SNRPatient 1 = 290 versus the other two cases (SNRPatient 4 = 27.4, SNRPatient 5 = 19.5) with more sclerotic appearances (Supplementary Figs. 1 and 3). This presents an intriguing concordance with PET literature in which osteolytic lesions have shown higher FDG uptake compared with osteoblastic ones [38,39,40] and glucose metabolism is known to be differently regulated in sclerotic versus lytic diseases [41].

Several key limitations should be identified for this pilot study. The correlation between metabolic biomarker kPL and total carbon SNR is yet to be elucidated in the mCRPC setting. In addition, the test–retest repeatability data are also needed moving forward. While the total carbon SNR reports tracer pharmacokinetics at each metastatic site, its quantitative accuracy can be further enhanced using automatic B1 calibration and correction for QC parameters. This study utilized a 2D single-slice imaging strategy. Future advancement in array receiver hardware [42] and MR acquisition sequences [21, 43] will enable full 3D coverage of the abdomen/pelvis and seamless integration with standard-of-care restaging scans. Dissemination of this technology, in terms of infrastructure and instruments, requires a clinical 13C polarizer and specialized MRI hardware. The on-site pharmaceutical manufacturing follows the same standard as PET, allowing for shared facility [14]. These capabilities can readily be instated in high-volume tertiary centers who manages the majority of the advanced prostate cancer cohort. Overall, future developments are warranted to address the technical needs including hardware, image acquisition and quantitative analyses, and the clinical inquiries deserve to be powered by a larger cohort study.

These preliminary results highlight the future need to metabolically characterize lymphadenopathy using HP 13C-pyruvate MRI, as management of nodal disease could be essential in the realm of biochemically recurrent and oligometastatic PCa [44,45,46,47]. For these cohorts of patients, opportunities for curative treatment are more available, and clinical outcomes are generally better than those with bone involvement and thus higher disease burden. Such future studies could be enabled by the aforementioned technical advancements to achieve higher resolution and sensitivity, and new pharmacy QC procedures that reduce HP 13C-pyruvate time-to-injection and thereby improving SNR [14].


This pilot study evaluated the safety and feasibility to conduct HP 13C MRI studies of patients with metastatic prostate cancer to the skeleton and viscera, which represents the most advanced and lethal form of the disease. Methods were examined and established for instrumentation setup, pharmacy manufacturing, image acquisition, and quantitative analysis. Safety was demonstrated and highly upregulated pyruvate-to-lactate conversion kPL was observed on aggressive osseous and hepatic metastases. Interval decrease of kPL was found for one patient receiving combination chemotherapy, in concordance with conventional clinical biochemical and imaging biomarkers. These findings warrant further development and investigation of HP 13C-pyruvate MRI in a larger prospective group of men with metastatic CRPC.


  1. Society AC. Cancer facts and figures 2019. Atlanta, GA: American Cancer Society; 2019.

  2. Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, et al. Rationale for modernising imaging in advanced prostate cancer. Eur Urol Focus. 2017;3:223–39.

    Article  Google Scholar 

  3. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028–38.

    Article  Google Scholar 

  4. Goodman OB Jr., Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34–9.

    CAS  Article  Google Scholar 

  5. Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270–3.

    CAS  Article  Google Scholar 

  6. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492–503.

    CAS  Article  Google Scholar 

  7. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148–59.

    Article  Google Scholar 

  8. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7:202–11.

    Article  Google Scholar 

  9. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81–4.

    CAS  Article  Google Scholar 

  10. Seitz AK, Rauscher I, Haller B, Krönke M, Luther S, Heck MM, et al. Preliminary results on response assessment using 68 Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602–12.

    CAS  Article  Google Scholar 

  11. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-C-13]Pyruvate. Sci Transl Med. 2013;5:198ra108

  12. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100:10158–63.

    CAS  Article  Google Scholar 

  13. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607–15.

    CAS  Article  Google Scholar 

  14. Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, et al. Hyperpolarized (13)C MRI: path to clinical translation in oncology. Neoplasia. 2018;21:1–16.

    Article  Google Scholar 

  15. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71:6921–5.

    CAS  Article  Google Scholar 

  16. Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927–30.

    CAS  Article  Google Scholar 

  17. Gonzalez PS, O’Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563:719–23.

    CAS  Article  Google Scholar 

  18. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010;9:33.

    Article  Google Scholar 

  19. Timm KN, Kennedy BW, Brindle KM. Imaging tumor metabolism to assess disease progression and treatment response. Clin Cancer Res. 2016;22:5196–203.

    CAS  Article  Google Scholar 

  20. Aggarwal R, Vigneron DB, Kurhanewicz J. Hyperpolarized 1-[(13)C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer. Eur Urol. 2017;72:1028–9.

    CAS  Article  Google Scholar 

  21. Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, et al. Technique development of 3D dynamic CS-EPSI for hyperpolarized (13) C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med. 2018;80:2062–72.

    CAS  Article  Google Scholar 

  22. Park I, Larson PEZ, Gordon JW, Carvajal L, Chen HY, Bok R, et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med. 2018;80:864–73.

    CAS  Article  Google Scholar 

  23. Brender JR, Kishimoto S, Merkle H, Reed G, Hurd RE, Chen AP, et al. PET by MRI: Glucose Imaging by 13C-MRS without dynamic nuclear polarization by noise suppression through tensor decomposition rank reduction. bioRxiv. 2018; preprint 15 February 2018;

  24. Nelson SJ, Brown TR. The accuracy of quantification from 1d nmr-spectra using the piqable algorithm. J Magn Reson. 1989;84:95–109.

    CAS  Google Scholar 

  25. Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M, et al. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR Biomed. 2018;31:e3997.

    Article  Google Scholar 

  26. Korn N, Larson PEZ, Chen H-Y, Gordon JW, Bok RA, Van Criekinge M, et al. The rate of hyperpolarized [1-13C] pyruvate to [1-13C] lactate conversion distinguishes high-grade prostate cancer from low-grade prostate cancer and normal peripheral zone tissue in patients. Proceedings of the 26th Annual Meeting of ISMRM, Paris France. 2018; International Society for Magnetic Resonance in Medicine.

  27. Mammoli D, Gordon J, Autry A, Larson PEZ, Li Y, Chen HY, et al. Kinetic modeling of hyperpolarized carbon-13 pyruvate metabolism in the human brain. IEEE Trans Med Imaging. 2019; e-pub ahead of print 2 July 2019;

  28. Bok R, Lee J, Sriram R, Keshari K, Sukumar S, Daneshmandi S, et al. The role of lactate metabolism in prostate cancer progression and metastases revealed by dual-agent hyperpolarized (13)C MRSI. Cancers. 2019;11:257.

  29. Hiew K, Hart CA, Ali A, Elliott T, Ramani V, Sangar V, et al. Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer. Eur Urol Focus. 2019;5:831–41.

  30. Koukourakis MI, Giatromanolaki A, Panteliadou M, Pouliliou SE, Chondrou PS, Mavropoulou S, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer. 2014;110:2217–23.

    CAS  Article  Google Scholar 

  31. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78–82.

    Article  Google Scholar 

  32. Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA Ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–52.

    CAS  Article  Google Scholar 

  33. Heiken JP, Bae KT. Contrast medium administration and scan timing for MDCT.  In: Marchal G, Vogl TJ, Heiken JP, Rubin GD (eds). Multidetector-Row Computed Tomography, Springer: New York 2005, pp 13–20.

  34. Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3:573–89.

    Article  Google Scholar 

  35. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–76.

    CAS  Article  Google Scholar 

  36. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.

    CAS  Article  Google Scholar 

  37. Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014;15:1521–32.

    Article  Google Scholar 

  38. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74.

    Article  Google Scholar 

  39. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.

    Article  Google Scholar 

  40. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–9.

    CAS  Article  Google Scholar 

  41. Todenhofer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:838202.

    Article  Google Scholar 

  42. Autry AW, Gordon JW, Carvajal L, Mareyam A, Chen HY, Park I, et al. Comparison between 8‐and 32‐channel phased‐array receive coils for in vivo hyperpolarized 13C imaging of the human brain. Magn Reson Med. 2019;82:833–41.

    CAS  Article  Google Scholar 

  43. Gordon JW, Chen HY, Autry A, Park I, Van Criekinge M, Mammoli D, et al. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magn Reson Med. 2019;81:2702–9.

  44. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43.

    Article  Google Scholar 

  45. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.

    CAS  Article  Google Scholar 

  46. Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: reality or figment of imagination? Cancer. 2019;125:340–52.

    Article  Google Scholar 

  47. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.

    Article  Google Scholar 

Download references


This work was supported by grants from the NIH (R01 CA183071, U01EB026412, R01CA215694, R01CA166655, U01CA232320, and P41EB013598).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Daniel B. Vigneron.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, HY., Aggarwal, R., Bok, R.A. et al. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis 23, 269–276 (2020).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links